Publications by authors named "Yulia Maxuitenko"

Claim this Profile
E
Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.
Daniela D De Nobrega, Logan C Eiler, Parmanand Ahirwar, Sonika Nallapu, Urvi P Rawal, Yulia Y Maxuitenko

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia.
Tyler W Jenkins, Jacquelyn Elise Fitzgerald, Jieun Park, Addison M Wilson, Kristy L Berry, Yulia Y Maxuitenko

Sci Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.
Sara Sigler, Mohammad Abdel-Halim, Reem K Fathalla, Luciana Madeira Da Silva, Adam B Keeton, Yulia Y Maxuitenko

Anticancer Agents Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest T Smith, Yulia Y Maxuitenko

Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models.
Daniela De Nobrega, Logan C Eiler, Parmanand Ahirwar, Urvi P Rawal, Chelsea L Crawford, Yulia Y Maxuitenko

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Yulia Y Maxuitenko

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest Smith, Yulia Y Maxuitenko

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Yulia Y Maxuitenko

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of KRAS inhibitors for colorectal cancer.
Gary A Piazza, Preethi Chandrasekaran, Yulia Y Maxuitenko, Karim I Budhwani

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.
Heather N Tinsley, Bini Mathew, Xi Chen, Yulia Y Maxuitenko, Nan Li

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Alexander B Coley, Antonio Ward, Adam B Keeton, Xi Chen, Yulia Maxuitenko

Adv Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Colon Tumorigenesis in Mutant Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin.
Kevin J Lee, Wen-Chi L Chang, Xi Chen, Jacob Valiyaveettil, Veronica Ramirez-Alcantara, Yulia Maxuitenko

Cancer Prev Res (Phila)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Mohammad Abdel-Halim, Sara Sigler, Nora A S Racheed, Amr Hefnawy, Reem K Fathalla, Yulia Maxuitenko

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
Antonio B Ward, Adam B Keeton, Xi Chen, Tyler E Mattox, Alex B Coley, Yulia Y Maxuitenko

MedComm (2020)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.
Gary A Piazza, Antonio Ward, Xi Chen, Yulia Maxuitenko, Alex Coley

Drug Discov Today· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy.
Aikaterini Emmanouilidi, Ilaria Casari, Begum Gokcen Akkaya, Tania Maffucci, Luc Furic, Yulia Y Maxuitenko

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Tyler E Mattox, Xi Chen, Yulia Y Maxuitenko, Adam B Keeton, Gary A Piazza

Int J Mol Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Aleksandra Adamska, Alice Domenichini, Emily Capone, Verena Damiani, Begum Gokcen Akkaya, Yulia Maxuitenko

J Exp Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.
Jaideep V Thottassery, Vijaya Sambandam, Paula W Allan, Joseph A Maddry, Yulia Y Maxuitenko

Cancer Chemother Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea.
Malari A Coburn, Sabrina Brueggemann, Shilpa Bhatia, Bing Cheng, Benjamin D L Li, Yulia Y Maxuitenko

Cancer Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Heather N Tinsley, Bernard D Gary, Jose Thaiparambil, Nan Li, Wenyan Lu, Yulia Y Maxuitenko

Cancer Prev Res (Phila)· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
Gary A Piazza, Adam B Keeton, Heather N Tinsley, Bernard D Gary, Jason D Whitt, Yulia Y Maxuitenko

Cancer Prev Res (Phila)· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.
Zhican Qu, Sabrina Van Ginkel, Anshu M Roy, Louise Westbrook, Mubina Nasrin, Yulia Maxuitenko

Cancer Res· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Christopher A Carter, Charles Chen, Cheryl Brink, Patrick Vincent, Yulia Y Maxuitenko

Cancer Chemother Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice.
Benjamin Frydman, Andrei V Blokhin, Sara Brummel, George Wilding, Yulia Maxuitenko

J Med Chem· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis